FDA Clears AI-based Reconstruction Technology for Cartesion Prime PET/CT System

Canon Medical has received US FDA clearance for Advanced intelligent Clear-IQ Engine (AiCE), the company’s deep learning reconstruction technology, on the Cartesion Prime Digital PET/CT System. The company will showcase the system at the upcoming virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting.

The Cartesion Prime with AiCE can help clinicians produce high-quality images consistently and routinely, paving the way for improved image quality, the ability to better visualize lesions and possibly reduce a patient’s time in the scanner.

AiCE was trained using vast amounts of high-quality data, and features a deep learning neural network that can reduce noise and boost signal to quickly deliver, clear and distinct images, further opening doors for advancements in molecular imaging. An innovative approach to reconstruction, AiCE on the Cartesion Prime Digital PET/CT can provide fast exams at a lower dose with better image quality than traditionally acquired during both the PET and CT acquisitions.

“We’re taking innovation in molecular imaging one step further than ever thought possible with the availability of DLR on a digital PET/CT system. Having AiCE provide improved image quality and faster scans at a lower dose for both PET and CT acquisitions will be critically important for clinicians to chart the right course for their patients’ care,” said Tim Nicholson, managing director, Molecular Imaging Business Unit, Canon Medical Systems USA, Inc. “As Canon Medical continues its expansion of AiCE into more modalities, it opens doors for more clinical applications to be made available